Google
Trusted Resources: People & Places
Healthcare providers, researchers, and advocates
David Beidler, PhD
Researcher Senior Director, Precision Medicine, Early Clinical Development
Pfizer Inc.
Global Research and Development -
Rare Diseases Research Unit
1 Portland Street
Cambridge, Massachusetts, United States
As the Translational Sciences lead for the phosphodiesterase type 9 inhibitor project, Dr. Beidler contributed to the development, implementation, and analysis of pharmacodynamic biomarkers in the recent phase 1b study in stable sickle cell disease subjects. Dr. Beidler has over 17 years of pharmaceutical industry experience with biomarker/translational pharmacology strategy and clinical operations that span preclinical animal models, natural history/methodology studies, and early (Phase 1/2) clinical trials. Dr. Beidler has also served as the research project team leader and in vivo pharmacology lead on several pain/inflammation project teams that delivered multiple candidate compounds to the clinic.
Representative Publications:
Safety and Tolerability of PF-04447943 across a Clinical Trial Program Including 277 Patients
+myBinderRelated Content
-
Red Cell Pain Management Service at St George’s HospitalPeople with sickle cell disease can ofte...
-
A Patient Advocate’s Take on Sickle Cell Disease: The Pain and the PromiseSeptember is National Sickle Cell Awaren...
-
Annual Sickle Cell Disease and Thalassaemia Conference (ASCAT) 2022The Annual Scientific Conference on Sick...
-
Acute Care Utilization in Pediatric Sickle Cell Disease and Sickle Cell Trait in the USA: Prevalence, Temporal Trend...The objective of this study was to analy...
-
Executive functioning and health-related quality of life in pediatric sickle cell diseaseResearch consistently indicates that chi...
-
Donald B. Kohn, MDDr. Donald Kohn, MD, is a Distinguished ...
-
Cincinnati Children’s Hospital Medical CenterThe Comprehensive Sickle Cell Center at ...
